Concert Pharmaceuticals Inc (NASDAQ: CNCE) looks to ride another Wave higher

(24/7 Market News) Concert Pharmaceuticals Inc (NASDAQ:CNCE) has already rode several waves to new highs, including hitting $6.50 this morning.

The Lexington, Massachusetts based clinical stage biopharmaceutical company is developing small molecule drugs, which it discovered through the application of its deuterated chemical entity platform. Its lead treatment candidate targets alopecia areata, a serious autoimmune dermatological condition, and is in late-stage development.

Concert Pharmaceuticals recently reported positive topline results for First CTP-543 Phase 3 clinical trial in Alopecia Areata and the highlights included; THRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses, Statistically Significant Hair Regrowth Observed as Early as Eight Weeks, CTP-543 Has Potential to be Best-in-Class for the Treatment of Alopecia Areata, and Topline Data from Second Phase 3 Trial, THRIVE-AA2, Expected Third Quarter of 2022

Concert Pharmaceuticals has retreated to $6.36, for a $1.34 (+26.63%) gain, on 2,338,264 shares, but, if it consolidates at this level and then breaks through the $6.45 level, we should see another wave higher.

24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.